Intuitive Surgical: The Godfather of Robotic Surgery

In the late 1990s, while most of Silicon Valley was chasing the dot-com boom, a scrappy startup called Intuitive Surgical was quietly rewriting the rules of surgery. Spun out of Stanford Research Institute (SRI) in 1995, Intuitive’s founders—Fred Moll, John Freund, and Rob Younge—envisioned a future where surgeons controlled robots with millimeter precision from across the room.

Their first product, the da Vinci Surgical System, launched in 1999 and was unlike anything the industry had seen. It combined endoscopic tools, 3D visualization, and robotic arms controlled via a surgeon’s console—bringing unprecedented dexterity and vision to minimally invasive surgery.

Hospitals were skeptical at first. The system was expensive (over $1M) and required a new way of operating. But Intuitive kept improving. By 2000, it went public. By 2003, the FDA cleared da Vinci for prostatectomies. That changed everything. Urologists drove adoption; soon, gynecologists and cardiothoracic surgeons followed.

From there, Intuitive built a classic flywheel: more installs → more trained surgeons → more procedures → more consumables revenue. Today, over 12 million surgeries have been performed with da Vinci systems, and Intuitive dominates the market with >80% share.

Its moat is deep: proprietary instruments, training programs, a razor-and-blade business model, and a 25-year head start. Still, challengers like CMR Surgical, Medtronic, and Johnson & Johnson are circling.

But for now, Intuitive remains the undisputed leader—a rare example of a hardware IPO that scaled to a $100B+ market cap and changed medicine forever.